Samrat Pharma's Q2 FY25 Shines: A Quarter of Impressive Growth!
Share- Nishadil
- November 24, 2025
- 0 Comments
- 2 minutes read
- 3 Views
Well, folks, it looks like Samrat Pharma has certainly had a fantastic run in the second quarter of the fiscal year 2025. The numbers for the period ending September 2025 are out, and they paint a remarkably vibrant picture of growth, especially when you consider the standalone figures. It’s the kind of report that makes you sit up and take notice, demonstrating some really strong momentum.
Let's dive into the specifics, shall we? The company’s standalone net sales for this quarter reached a robust Rs 78.87 crore. Now, comparing that to the same period last year, where sales stood at Rs 70.17 crore, we're looking at a very respectable 12.4% increase. That’s a pretty healthy uptick, showcasing a solid expansion in their top line.
But honestly, where Samrat Pharma truly excelled was on the profitability front. The Profit Before Tax (PBT) absolutely surged to Rs 1.77 crore in Q2 FY25. This is a monumental jump from the Rs 0.87 crore reported in the September 2024 quarter, marking an astonishing increase of 104.05%. Yes, you read that right – it more than doubled! It’s clear they’ve managed their operations incredibly efficiently.
Following suit, the net profit tells an even more compelling story. Samrat Pharma's standalone net profit for the quarter soared to Rs 1.33 crore. This represents an incredible 104.62% rise compared to the Rs 0.65 crore recorded in the corresponding quarter of the previous fiscal year. Such a significant leap in the bottom line really underscores a powerful performance and, let’s be honest, it’s quite exciting to see.
And for those who keep a keen eye on shareholder value, the Earnings Per Share (EPS) figures are equally impressive. The company's EPS clocked in at Rs 0.44 for the September 2025 quarter, a neat 100% increase from the Rs 0.22 reported in Q2 FY24. This kind of double-digit growth across sales and triple-digit growth in profitability metrics certainly bodes well and suggests Samrat Pharma is navigating the market with considerable skill. It's definitely a quarter to remember for them, painting a very optimistic outlook.
Disclaimer: This article was generated in part using artificial intelligence and may contain errors or omissions. The content is provided for informational purposes only and does not constitute professional advice. We makes no representations or warranties regarding its accuracy, completeness, or reliability. Readers are advised to verify the information independently before relying on